Kyras Therapeutics Obtains Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3423f19a-fa87-48c7-bbf5-52ed0d09281e - Date
12/14/2015 - Company Name
Kyras Therapeutics - Mailing Address
54 West 21st Street New York, NY 10010 USA - Company Description
Kyras is a biopharmaceutical company developing drugs that address currently incurable cancers and developmental disorders caused by RAS gene mutations. We are a team of experienced scientists, drug developers, and entrepreneurs dedicated to advancing novel medicines to improve patients’ lives. - Website
http://www.kyrasrx.com - Transaction Type
Venture Equity - Transaction Amount
Undisclosed - Transaction Round
Series A - Proceeds Purposes
The company will use the funds to develop the RAS family of proteins. - M&A Terms
- Venture Investor
Versant Ventures - Venture Investor
Investor - Venture Investor
Investor
